Mobilization of DC precursors and Treg cells in patients receiving growth factor support. The frequency of DC1 (lineage-HLA-DR+CD11c+) and DC2 (lineage-HLA-DR+CD123+) precursors and that of CD4+FoxP3+ Treg cells was estimated by flow cytometry, as detailed in Materials and Methods. Panel A: Gating strategy for the enumeration of DC1 and DC2 precursors. Cells were initially gated based on lack of surface antigens associated with blood cell lineages. The co-expression of HLA-DR and CD11c or CD123 is shown in one patient given pegfilgrastim, and is representative of 12 independent experiments. Panel B: Cumulative frequency of DC1 (empty bars) and DC2 (black bars) in patients given pegfilgrastim or filgrastim. Median values and interquartile range are shown. *p < 0.05 compared with baseline. **p < 0.01 compared with baseline. Panel C: Boxes and whiskers depicting median values and interquartile range. *p = 0.01 compared with healthy controls (black bar); **p = 0.0009 compared with healthy controls (black bar). The Kruskal-Wallis test with Dunn's correction for multiple comparisons was used for statistical analyses. Panel D: Representative flow cytometry profile from one patient treated with pegfilgrastim. Quadrants were set according to the proper isotypic control (not shown). The percentage of CD4+FoxP3+ T cells in indicated.